

The idea of a medical cyclotron facility was mooted in 2007. Alarmed by the six-month waitlist for a PET-CT scan for a close family member, on account of the irregular supply of PET radiotracers, Dr. Amit Maniar and his team embarked on a global tour to understand the PET industry. Since PET radiotracers like F18 have a short half-life (~110 minutes), the logistics in terms of delivery becomes complex. The need for a reliable PET radiotracer supplier in India was apparent to Dr. Amit Maniar. This proved to be the terminus a quo for Shreeji.
The project was commercially operational in 2008 despite the innumerable regulatory and technical challenges. To cater to markets beyond road serviceable areas in and around Mumbai, Shreeji along with GE worked hard with the government and airlines to secure the necessary clearances for safe supply of FDG by flight.
With the assurance of FDG supply from Shreeji, PET-CT markets opened up across India in Chennai, Hyderabad, Ahmedabad, Vadodara, Kolkata, Kochi, Jaipur, Indore, Nagpur, and beyond. In 2011, Shreeji accepted the challenge to deliver FDG to Colombo, paving the way for the first PET-CT in Sri Lanka. Similarly, in 2015, our commitment led to the establishment of the first PET-CT in Nepal.
In 2017, Shreeji’s second medical cyclotron facility at IMT Manesar became operational. It was commissioned in a record 9 months – a cGMP-ready facility, a testament to the expertise, project execution capability, and uncompromising commitment to quality.
Between the Mumbai and Delhi facilities, Shreeji currently has an unrivaled distribution network across India making PET radiotracers conceivable and accessible to hospitals/diagnostic centers in cities, towns, and villages.
2011
2009
2008
2019
2014
2009
2020
2020
2020
2017
2011
2008
2013
2019
2019
2021
2019
2018
2008
2008
2014
2013
2021
2012
2009
2014
2009
2021
2011
2014
2021
2014
2014
2015
2020
2018
2013
2020
2010
2017
2017
2017
2018
2018
2018
2016
2020
2017
2017
2018
2018
2017
2021
2021
2021
2021
| Year | Location |
|---|---|
| 2008 | Chennai, Hyderabad, Pune, Mumbai |
| 2009 | Kochi, Kolkata, Vadodara, Ahmedabad |
| 2010 | Jaipur |
| 2011 | Colombo, Nagpur, Indore |
| 2012 | Surat |
| 2013 | Bengaluru, Aurangabad, Lucknow |
| 2014 | Bhubaneshwar, Nashik, Rajkot, Bhopal, Varanasi, Patna |
| 2015 | Kathmandu, |
| 2016 | Delhi, |
| 2017 | Raipur, Mathura, Faridabad, Gurgaon, Hisar, Mohali, Srinagar |
| 2018 | Satara, Kanpur, Ghaziabad, Noida, Meerut, Ludhiana, Jalandhar |
| 2019 | Visakhapatnam, Belgaum, Miraj, Sangli |
| 2020 | Imphal, Guwahati, Jamshedpur, Gorakhpur, Jodhpur, Rohtak |
| 2021 | Chiplun, Navsari, Udaipur, Gwalior, Solapur, Kolhapur, Bikaner, Ranchi |


Largest production
capacity in India and
flexible manufacturing
processes

Widest PET radiotracer
portfolio in India



Project execution
experience for scaling
operations

At Shreeji, we envision the future of healthcare to be precision care with radiotracers at the forefront of the revolution.

We seek to leverage our cGMP-ready facilities and distribution network to provide access to the
widest range of novel
tracers and radiotracers, to
arm medical practitioners
with the necessary
information and tools for
precise diagnoses and
bespoke therapy.

We are always exploring possibilities to collaborate with academic centers, pharmaceutical companies, and biotech firms to chart new pathways for the future.

Ultimately, we aspire to evolve to be a global leader in theranostics with a strong foundation in manufacturing and research.

Keeping with our ethos of improving access to the underserved, the company had earmarked funds for promoting healthcare, specifically, reducing child mortality and combating immune deficiency disease among children. The Company has supported the project titled “Diagnosis and Management of Inborn Errors of Immunity and Related Diseases” at the Department of Immunology, Bai Jerbai Wadia Hospital for Children, Mumbai. Primary Immunodeficiencies (PID) are inherited diseases of the immune system, which render these patients susceptible to serious, and often life-threatening infection and cancer. There are more than 10 million children and adults with primary immunodeficiency worldwide; more than one-half million in the U.S., and more than a million in India. A large number of patients with PIDs are not even diagnosed. Generally, PID is more severe in children than in adults. In India, there are very few institutions where patients with PIDs are diagnosed or treated; the majority of patients remain undiagnosed and die, contributing in part to India’s high infant mortality rate.
The project will support the Department of Immunology to, inter alia:

Dr. Amit founded Shreeji in 1990 and is part of its Board of Directors. He began his career as a consulting Sonologist in 1987 but soon realized his desire to improve the quality and accessibility of medical diagnostics in India. Under Dr. Amit’s leadership and despite financial constraints, Shreeji procured the first CT scanner in a remote suburb of Mumbai in 1992 and an MRI in 1997 – transforming the entire suburban diagnostic market in Mumbai. It also pioneered the introduction of several revolutionary modalities such as India’s first multi-slice CT scanner and Asia’s first Cardiac CT scanner, among others.
Dr. Amit is also responsible for the Company’s successful venture into the PET cyclotron industry in 2007. His project execution skills were instrumental in setting up Shreeji’s IMT Manesar cyclotron facility in record 9 months.
Dr. Amit believes the future of healthcare will be personalized medicine with radiotracers playing an integral role. He seeks to guide Shreeji to its goal of becoming a global leader in theranostics.
Dr. Amit completed his doctorate of medicine in Radiology from Topiwala National Medical College and BYL Nair Charitable Hospital, Mumbai, and was a visiting fellow at the Thomas Jefferson University, USA. He resides in Mumbai along with his wife, Meera (co-founder), and their two children, Kunal and Advit.

Meera is the co-founder of Shreeji and a distinguished chartered accountant with over 30 years of experience. She is part of Shreeji’s Board of Directors. Meera is responsible for the financial affairs of the company along with risk assessment on projects. Her financial management and administrative skills have been pivotal in the Company’s capital-intensive and debt-funded growth story. Meera’s efforts have been integral for Shreeji’s success in the diagnostics and cyclotron business.
Prior to Shreeji, Meera was engaged in tax and auditing consultancy. She completed her bachelor of commerce from Narsee Monjee College of Commerce and Economics, Mumbai in 1985 and her Financial Chartered Accountancy in 1988.
She resides in Mumbai along with her husband, Amit (co-founder), and their two children, Kunal and Advit. She holds a deep interest in philosophy and spirituality.

Kunal joined Shreeji in 2019. He leads the technical operations department and is responsible for quality control, novel radiotracers development, and strategic collaborations. He has realized synergies and processes to improve system performance, reliability, and efficiency.
His contributions were key in making 18F-PSMA and 18F-DOPA accessible to the entire country and is working hard to achieve the same with 18F-FES. Kunal believes that novel PET isotopes are important tools for improving patient diagnoses, treatment, and overall quality of life. He is focused on increasing access and availability in the market whilst looking for opportunities for collaboration with universities, pharmaceutical companies, and biotech firms.
Kunal holds a doctorate in Pharmacology from the Post Graduate Institute of Medical Education and Research, Chandigarh, and has multiple peer-reviewed publications to his name. He resides in Mumbai with his wife and is an avid cyclist and motor enthusiast.

Advit joined our team in 2018. In his role, he leads all the commercial activities, supports business development, growth initiatives, regulatory compliance, and legal affairs. In his time at Shreeji, he has increased the client base, optimized cost and supply chains, implemented scalable processes, and increased focus on the use of digital tools to further the Company’s goals. His vision is to reinforce the company’s leadership position in India and expand its borders to a global stage to ensure that Shreeji remains on a consistent, sustainable, and profitable growth track.
Before joining Shreeji, Advit was a corporate lawyer at Cyril Amarchand Mangaldas with experience in Project Finance, Employment, and Funds practice areas. He holds an honors degree in Bachelor of Arts and Law from the National Law Institute University, Bhopal. Advit currently resides in Mumbai. In his free time, he likes to run and enjoys an occasional game of football.
